vida: extract claims from 2026-05-07-psychiatric-news-apa-glp1-aud-off-label

- Source: inbox/queue/2026-05-07-psychiatric-news-apa-glp1-aud-off-label.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md

@@ -31,3 +31,10 @@ The Psychopharmacology Institute — a CME platform for practicing psychiatrists
 **Source:** Dr. Will Sauvé, Osmind CMO
 
 Osmind CMO Dr. Sauvé frames competency gap as existential for psychiatry: 'If our field of psychiatry does not get a hundred percent ahead of how this GLP thing works, then we're going to be left behind.' Identifies specific gap: psychiatrists managing GLP-1-prescribed patients without understanding central mechanisms, dosing nuances, or psychiatric side effects.
+
+
+## Supporting Evidence
+
+**Source:** Psychiatric News (APA), February 2026
+
+APA's Psychiatric News (February 2026) recommends GLP-1 RAs as second-line AUD treatment requiring metabolic comorbidity, despite JAMA Psychiatry 2025 showing 41.1% reduction in heavy drinking days (NNT 4.3) in AUD + obesity population. The conservative framing (second-line, comorbidity required) contrasts with evidence supporting first-line efficacy. Individual psychiatrists prescribing to >60 patients report 60-70% response rates for alcohol and nicotine reduction, but APA-adjacent guidance maintains naltrexone/acamprosate as first-line despite inferior NNT.

domains/health/glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence.md

@@ -24,3 +24,10 @@ This systematic review of 80 RCTs (107,860 participants) plus large cohort studi
 **Source:** Gill et al., JAMA Psychiatry 2026
 
 MDD trial used oral semaglutide 14mg (therapeutic weight-loss dose range) and showed motivation improvement, contrasting with high-dose anhedonia reports. No dose-response curve was tested within the trial, leaving the therapeutic window undefined despite positive findings.
+
+
+## Supporting Evidence
+
+**Source:** Psychiatric News (APA), February 2026
+
+APA-adjacent guidance (Psychiatric News, February 2026) provides no dose management protocol or psychiatric monitoring recommendations for GLP-1 use in AUD, despite recommending off-label prescribing for metabolically comorbid patients. The guidance focuses solely on efficacy data without engaging with anhedonia risk, dose titration, or psychiatric side effect monitoring.

domains/health/semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population.md

@@ -25,3 +25,10 @@ The SEMALCO trial (N=108, 26 weeks, double-blind RCT) demonstrated semaglutide 2
 **Source:** Osmind clinical article Q1 2026
 
 Osmind states GLP-1s for AUD show 'effect sizes exceeding those historically seen with naltrexone or acamprosate' based on 2025 JAMA Psychiatry trial, confirming superior efficacy claim with specific comparator medications.
+
+
+## Supporting Evidence
+
+**Source:** Psychiatric News (APA), February 2026
+
+APA's Psychiatric News cites the 41.1% reduction in heavy drinking days (NNT 4.3) from JAMA Psychiatry 2025 as key efficacy data, but recommends GLP-1 RAs only as second-line treatment for patients with comorbid metabolic disease who are non-responsive to standard treatments. This creates evidence-to-guideline lag where superior NNT doesn't translate to first-line recommendation.

inbox/archive/health/2026-05-07-psychiatric-news-apa-glp1-aud-off-label.md

@@ -7,10 +7,13 @@ date: 2026-02-01
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-07
 priority: medium
 tags: [glp-1, AUD, off-label, psychiatry, APA, prescribing-guidance]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content